SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the Trump administration is reportedly in talks to take equity stakes in quantum computing firms, potentially providing a boost to the sector. The community is actively discussing the implications of this government involvement and whether it will trigger a short squeeze. Amidst this news, there are debates regarding the company's valuation and future prospects within the quantum computing landscape.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending amid discussions of potential government investment in quantum computing firms, sparking debates about the sector's speculative nature and long-term potential.  Community members are weighing the significance of this backing, while some express skepticism about the technology's current valuation and practical applications. The news is driving volatility, with both bulls and bears actively strategizing around potential price movements.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid discussions about a potential equity stake from the Trump administration in exchange for federal funding, as reported by the WSJ. Community chatter revolves around the potential impact of this news, with some anticipating a short squeeze while others express skepticism about the amount of funding. There is debate about how this government involvement will impact the quantum computing sector, which also includes names such as IONQ and RGTI.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp is trending as discussion centers around the potential impact of government investment in quantum computing firms and the company's positioning with its 'Made in USA' post-quantum chips. Community members are actively debating the possibility of a short squeeze, comparing it to past events with other quantum stocks, while also pointing to potential government contracts on the horizon. Talk also focuses on the impact of the latest stock offering on price action.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as discussions revolve around its potential as a leading quantum computing play following recent volatility in the sector. Some investors believe the stock is currently undervalued compared to its peers, especially with the upcoming Q+AI Conference and its partnership with NVIDIA. The community is weighing the risks and potential rewards ahead of the merger, with some drawing comparisons to other high-growth SPACs.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla ($TSLA) is trending as investors digest its latest earnings report, with key talking points revolving around AI advancements and the future of robotaxis. The community is actively debating the company's profitability, growth prospects, and Elon Musk's vision amid discussions of potential market overvaluation. Sentiment appears mixed, with some expressing concerns about margins and future performance, while others remain optimistic about Tesla's long-term potential in AI and robotics.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle ($CRCL) is trending amid community discussion around large, out-of-the-money call option buying, specifically the Nov 21 $385 strike, which some speculate could be tied to potential acquisition news or regulatory changes. Some traders are pointing to the upcoming lockup period expiration and earnings as potential catalysts, while others highlight Wells Fargo's updated overweight rating with a $160 price target as a positive signal.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded in 1989 and is headquartered in Los Angeles, CA.

Armata Pharmaceuticals Inc

Armata Pharmaceuticals ($ARMP) is trending after promising Phase 2a trial results for its phage therapy targeting Staph aureus bacteremia, with community members highlighting the potential for a new standard of care and the stock's volatile price action. Bullish sentiment focuses on the news catalyst, small float, and backing from Innoviva and the U.S. government, while bears cite potential dilution and historical volatility.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending due to positive reactions to the company's quantum computing advancements, specifically its partnership with HSBC to improve bond-trading predictions, causing a significant market cap increase. Community discussions highlight IBM's potential in AI and quantum computing, with some seeing it as undervalued compared to other quantum stocks. However, the stock experienced after-hours volatility despite a Q3 revenue beat and raised guidance, leading to mixed sentiments about short-term performance.

Houston American Energy Corp. is an independent oil and gas company, which engages in the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. The firm holds interest in the Texas Permian Basin, the onshore Texas and Louisiana Gulf Coast region and in the South American country of Colombia. It operates through the North America and South America geographical segments. The company was founded on April 2, 2001 and is headquartered in Houston, TX.

Houston American Energy Corp

HUSA is trending due to discussions around its potential in the oil sector amid geopolitical tensions and sanctions, with community members weighing its low float and possible breakouts. Some traders are actively debating the company's fundamentals and potential for a short squeeze, while others discuss specific price levels as possible entry or exit points. Recent news and technical analysis are fueling the discussions, although opinions on the stock's future direction remain divided.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuron (IMRN) CEO Steven Lydeamore stated in a letter to shareholders on Thursday that the company does not anticipate any material impact from the recently announced U.S. tariffs on pharmaceutical products.Nasdaq-listed shares of Immuron rallied 8% on Thursday morning following the news. The CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html">stated</a> that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.The Australia-based company also said that it is on track to exceed FY24 first-quarter (Q1) sales. The company is slated to report its Q1 FY25 sales in mid-October.Immuron has three therapeutic products under development, including IMM-124E, also known as Travelan, for traveler’s diarrhea. The company stated that it continues to expect trial results for this candidate in October 2025.“It is hoped that this trial will enable Travelan to be recommended in traveler’s diarrhea guidelines, thereby increasing its market potential,” the company said.As for IMM-529, which is under development for Clostridioides difficile infection, Immuron stated that it is progressing with an application to the U.S. Food and Drug Administration to initiate clinical development by mid-October. According to Immuron, the IMM-529 market in the U.S. is expected to reach peak revenues of approximately $400 million.The company has also advanced the launch of ProIBS, a medical product for treating symptoms related to Irritable Bowel Syndrome, to the fourth quarter from its previous estimate of Q1 2026. Immuron now anticipates a limited launch in Q4, with a full launch in Q1 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:574/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_12_28_03_PM_png_c36282e1fb.webp" alt="IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="574" height="58"><figcaption>IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s updates.<stembedurl>https://stocktwits.com/Timtheshark/message/630768842</stembedurl>IMRN stock is up 22% this year but down approximately 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 

Equity

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Limited CEO to Present at Biotech Event

Immuron Limited (AU:IMC) has released an update. Immuron Limited, an Australian biopharmaceutical company, will feature CEO Steven Lydeamore presen...

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers...

12 titres de soins de sant  en mouvement lors de la session apr s-cl ture le 07/03/2024

Gagnants
Le titre Ainos (NASDAQ:AIMD) a grimp jeudi de 101,78% 2,26 dollars lors de la session after-market.
Le titre Immuron (NASDAQ:IMRN) a grimp de 36,26% 6,20 dollars.
L'action Talis...

Immuron Announces Positive Results Support Travelan  progress to Phase 3 Clinical Trials in the US

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDATravelan topline clinical trial results demonstrate protective efficacy with single daily dose36.4% protective efficacy...

Immuron Presentation Australian Biologics Festival 2024

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron achieves record Travelan  sales

Highlights: Travelan sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 millionAustralian Travelan YTD Jan 2024 sales $2.1 millionUSA Travelan YTD Jan 2024 sales $0.6...

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our...

Immuron achieves record half yearly Travelan  sales

Highlights: Record half yearly Travelan sales of $2,334,969Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales51% higher than pre-pandemic period H1, FY20 sales...

Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

IMRN
IMMURON Ltd/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IMRN News

IMRNIMMURON Ltd/S ADR